Ebrahim Variava to Drug Administration Schedule
This is a "connection" page, showing publications Ebrahim Variava has written about Drug Administration Schedule.
Connection Strength
0,242
-
Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):577-579.
Score: 0,141
-
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019 12; 7(12):1048-1058.
Score: 0,041
-
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019 03; 7(3):249-259.
Score: 0,039
-
Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J. 2010 Sep 07; 100(9):566, 568, 570-1.
Score: 0,022